The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global thrombectomy devices market grew at a CAGR of around 5% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Thrombectomy devices offer numerous benefits in surrogate endpoints, such as biomarker analysis, infarct size reduction, ST-segment resolution and angiographic thrombolysis in myocardial infarction (TIMI) flow. These devices minimize blood loss and damage caused to the vessel wall during a procedure. Consequently, they find application in treating blood clots present in veins, arteries and capillaries. They are also used to treat pulmonary embolism and peripheral arterial diseases. At present, they are widely available in different sizes and diameters, depending on the affected area. Some of the most frequently used thrombectomy devices procedures are balloon embolectomy, surgical embolectomy and aspiration embolectomy.
According to the World Health Organization (WHO), chronic diseases are the leading causes of death and disability around the world. Disease rates from these conditions are accelerating significantly on account of hectic schedules, sedentary lifestyles, rising consumption of fast food and the increasing number of individuals who smoke and consume alcohol. This represents one of the key factors propelling the growth of the thrombectomy devices market worldwide. Moreover, the growing geriatric population, along with the escalating demand for minimally invasive (MI) procedures and improving healthcare infrastructure in various countries, is also fueling the growth of the market. Furthermore, the leading manufacturers are increasing their investments in research and development (R&D) activities to introduce technologically advanced thrombectomy devices, which, in turn, is creating a positive outlook for the market. Besides this, favorable medical reimbursements and rising preference of these devices by surgeons for performing image-guided surgeries are anticipated to strengthen the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global thrombectomy devices market report, along with forecasts for growth at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, product type, application, and end-user.
Breakup by Product Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Argon Medical Devices Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson, Medtronic Plc, Penumbra Inc., Spectranetics Corporation (Koninklijke Philips N.V.), Stryker Corporation, Teleflex Incorporated and Terumo Corporation.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at